



Alector is a clinical-stage biopharmaceutical company, develops therapies for the treatment of neurodegeneration diseases. Its products include **AL001**, that is in **Phase 2** clinical trial for the treatment of frontotemporal dementia disease and **AL101** that is in **Phase 1** clinical trial for the treatment of neurodegenerative diseases. The company also offers **AL002** and **AL003**, which are in **Phase 1b** clinical trials for the treatment of Alzheimer's disease.



On the following chart, the market capitalization of **Alector** is depicted in \$M. The company's financial underperformance led to a significant capitalization decline in Q3 2020. The results of a **Phase 2** study of **AL002** in participants with early Alzheimer's Disease were perceived negatively by the market, which exacerbated the further decline.



Source: ClinicalTrials.gov, Koyfin

Biophytis is a clinical-stage biotechnology company, focuses on the development of therapeutics that slow the degenerative processes and improve functional outcomes for patients suffering from age-related diseases. The two main medicines are **Sarconeos (BIO101)** from the treatment of neuromuscular diseases and **Macuneos (BIO201)** from the treatment of retinal diseases.



On the following chart, the market capitalization of **Biophytis** is depicted in \$M. Great capitalization performance of the company is obtained due to the good financial and medical pipeline performance, including success in the COVA clinical studies, additionally, Biophytis receives \$1.16M DeepTech Funding from BPI France for the Development of Macuneos (BIO201) in Dry AMD.



Source: ClinicalTrials.gov, Koyfin


ChromaDex operates as a bioscience company focusing on healthy aging. The company operates through three segments: Consumer products; Ingredients; and Analytical Reference Standards and Services.

On the following chart, the market capitalization of **ChromaDex** is depicted as \$M. When the company launched results “New **Phase 3** Clinical Study Finds Nutritional Protocol Including **Nicotinamide Riboside Accelerates Recovery in Mild-to-Moderate COVID-19 Patients**” the market overreacted during the first days, but after correction the capitalisation doubled thanks to this release.



CohBar is a clinical stage biotechnology company, engages in the research and development of mitochondria based therapeutics (MBTs) for the treatment of chronic and age-related diseases. Its lead MBT candidate is CB4211 in Phase Ib stage of a Phase Ia/Ib clinical trial. The company's preclinical programs include CB5138 analogs for fibrotic diseases, CB5064 analogs for COVID-19 associated ARDS, MBT5 analogs for CXCR4-related cancer and orphan diseases, and MBT3 analogs for cancer immunotherapy.



On the following chart, the market capitalization of **CohBar** is depicted in \$M. The spikes were gained due to the fact that the company has completed dosing in its Phase 1b study evaluating CB4211 as potential treatments for NASH and obesity.



Source: ClinicalTrials.gov, Koyfin

Denali Therapeutics is a biopharmaceutical company, discovers and develops therapeutic candidates for neurodegenerative diseases in the United States. The company offers leucine-rich repeat kinase 2 (**LRRK2**) inhibitor product candidates, including **DNL201** that has completed **Phase 1b**, and **DNL151**, which are in **Phase 1** and **Phase 1b**.



On the following chart the market capitalization of Denali Therapeutics is depicted in \$M. The significant spike in the capitalization of the company is gained due to the both strong financial performance in the past year and success in **Phase 1/2** study of **DNL310** in patients with Hunter syndrome (MPS II) and **Phase 1b** study of **DNL151**.



Source: ClinicalTrials.gov, Koyfin

GenSight Biologics is a clinical-stage biotechnology company, engages in the discovery and development of therapies for mitochondrial and neurodegenerative diseases of the eye and central nervous system.

On the following chart, the market capitalization of **GenSight Biologics** is depicted in \$M. The skyrocketing capitalization of the company is based on the good medical pipeline performance, namely **Phase III** trials of LUMEVOQ® (GS010) for the treatment of Leber Hereditary Optic Neuropathy (LHON) are **completed**. The manufacturing process also seems to be quite stable, since the company's **CDMO** is **Thermo Fischer Scientific**.





Source: ClinicalTrials.gov, Koyfin

Lineage Cell Therapeutics



Lineage Cell Therapeutics is a clinical-stage biotechnology company, focuses on developing and commercializing therapies for the treatment of degenerative diseases in the United States and internationally.

On the following chart, the market capitalization of **Lineage Cell Therapeutics** is depicted in \$M. The company has positive capitalization dynamic in 2021 based on the present positive clinical update from the ongoing **Phase 1/2a** study of OpRegen for the treatment of dry-AMD with GA; the company also reported **the first known finding of retinal tissue restoration** in a patient who received a retinal pigment epithelium (RPE) cell transplant continues to demonstrate areas of retinal restoration as of their last assessment, approximately 3 years after treatment.



Mesoblast Limited is a biopharmaceutical company, develops and commercializes allogeneic cellular medicines. The company offers products in the areas of cardiovascular, spine orthopedic disorder, oncology, hematology, and immune-mediated and inflammatory diseases.

On the following chart, the market capitalization of **Mesoblast** is depicted in \$M. In December 2020 **Mesoblast Ltd.** saw its stock drop on the news that its allogeneic mesenchymal cell therapy, **rexlemestrocel-L (Revascor)**, failed to meet the primary endpoint of a reduction in hospitalizations in its **Phase 3** advanced chronic heart failure trial.





Source: ClinicalTrials.gov, Koyfin

Stealth BioTherapeutics



Stealth BioTherapeutics (MITO) is a clinical-stage biotechnology company, focuses on the discovery, development, and commercialization of therapies for diseases involving mitochondrial dysfunction. Its lead product candidates: Elamipretide, SBT-20, SBT-272. The market capitalization of the company is depicted in \$M. **MITO** shares have fallen 26.40% over the year. However, they have moved up 9.85% at the beginning of June 2021 after the past three months' decline of market capitalization. In April 2021, the company delayed an NDA filing for elamipretide for cardiomyopathy in Barth syndrome that led to a 10% fall in capitalization. Besides that, **Stealth BioTherapeutics Corp** has reached an agreement with Morningside Ventures for Morningside to provide \$30M of additional payments to the Company during 2021, which helps to do more clinical trials.



Source: ClinicalTrials.gov, Koyfin

Unity Biotechnology

Unity Biotechnology is a biotechnology company, engaged in the research and development of therapeutics to extend human healthspan. The company's lead drug candidates include **UBX0101** that is in **Phase II** clinical trial for musculoskeletal/ osteoarthritis disease, as well as Phase Ib clinical trial for moderate-to-severe osteoarthritis of the knee.

On the following chart, the market capitalization of Unity Biotechnology is depicted in \$M. A significant drop in capitalization is gained due to the **UBX0101 Phase II** failure.

